RDHL has been in the news 462% more than usual
Jan 08, 2026, 3:33 PM
-15.87%
What does RDHL do
RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: Amir Reichman, CEO of Scinai Immunotherapeutics Ltd., will co-lead a roundtable on biopharma manufacturing in Israel on January 19, 2026, during HealthIL Week. Additionally, a BCG report indicates that the biopharma sector is facing significant financial pressures and risks, despite a favorable environment for larger biotech companies due to lucrative licensing deals and drug approvals.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.